Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Health systems and care delivery

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

A total of 144 surveys were collected from VA clinicians at baseline and during audit-feedback sessions (Table). Difficulty diagnosing AD and time constraints related to discussion of treatment options were the greatest challenges in managing AD among identified by providers. Clinicians identified patient hesitancy in discussing symptoms of dementia and challenges in distinguishing between normal aging from dementia symptoms as top factors which contributed to delayed diagnosis of AD. In patients diagnosed with early AD, difficulties with care coordination and patients' mental (eg cognitive impairment) or social issues (eg behavioral changes) were the main reasons eligible patients did not receive DMTs. Clinical pathway or formulary restrictions and lack of time to align treatment paradigms with emerging evidence were identified as additional challenges to administering DMTs to eligible patients. Following the sessions, process changes included implementation of a cognitive testing workflow, improvements to documentation of screening and assessment in the EMR, education for clinicians to support shared treatment decision-making with patients, and formation of a dementia care working group. These findings highlight barriers in early diagnosis and management of AD in the VA setting. Action plans designed to address these barriers have resulted in implementation of process improvements.

What this study adds

Evidence grade: Low

The record lists 144 participants. This survey of VA clinicians identified barriers to diagnosing Alzheimer's disease and to delivering disease-modifying treatments, and led to process changes such as a cognitive testing workflow. It does not test a treatment, cure, or prevention for Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kapoor, A., Carter, J., Landau, E., Napolitan, C., Simone, L., Jarzylo, L. A., et al. (2025). Examining Barriers and Strategies to Improve Alzheimer's Disease Care in the Veterans Affairs Setting. Alzheimer s & Dementia. https://doi.org/10.1002/alz70858_102944

Vancouver

Kapoor A, Carter J, Landau E, Napolitan C, Simone L, Jarzylo LA, et al. Examining Barriers and Strategies to Improve Alzheimer's Disease Care in the Veterans Affairs Setting. Alzheimer s & Dementia. 2025. doi:10.1002/alz70858_102944. PMID: 41445135.

BibTeX

@article{kapoor2025-41445135,
  author  = {Kapoor, Arushi and Carter, Jeffrey and Landau, Emma and Napolitan, Chris and Simone, Laura and Jarzylo, Larissa A. and Budson, Andrew E.},
  title   = {{Examining Barriers and Strategies to Improve Alzheimer's Disease Care in the Veterans Affairs Setting}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70858_102944},
  pmid    = {41445135},
  url     = {https://doi.org/10.1002/alz70858_102944}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This survey of VA clinicians identified barriers to diagnosing Alzheimer's disease and to delivering disease-modifying treatments, and led to process changes such as a cognitive testing workflow. It does not test a treatment, cure, or prevention for Alzheimer's disease.

Study details

How this study scored 37/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 37 of 100.37 of 100 points earned63 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 144 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Andrew E. Budson: h-index 72 (OpenAlex, whole career)
Institution's track record 1 / 3 Boston University: institution h-index 1,456 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41445135)
Free to read 2 / 2 Free to read
Total 37 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Health systems and care delivery from nearby years

Also in Health systems and care delivery

172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.

Similar studies

More on Health systems and care delivery

See all studies in Health systems and care delivery →